Navigation Links
Gamma Pharmaceuticals Accepts PO From Leading St. Louis Missouri Distributor. Order Valued up to $850,000 Retail Market Value
Date:3/12/2009

LAS VEGAS, March 12 /PRNewswire-FirstCall/ -- Gamma Pharmaceuticals Inc. (OTC Bulletin Board: GMPM) announces the receipt of purchase orders for its Jugular(R) brand Energy Products from Folsom Distributing in St. Louis, Missouri. Folsom Distributing services the QuikTrip Convenience Store outlets in St. Louis and the surrounding area. QuikTrip requested Folsom Distributing to contract directly with Gamma on its behalf. Gamma has developed a series of programs to promote its branded products. Gamma estimates that its brand promotion program developed for the St. Louis Market should result in revenue of up to $850,000 in the territory over the next 12 months. Gamma's CEO Peter Cunningham commented, "Our QuikTrip relationship will significantly boost Gamma's Jugular(R) branded products in this important market. We feel QuikTrip, the premier convenience store chain in St. Louis, will drive our market share performance and overall brand profile."

Gamma Pharmaceuticals Inc. is a marketing and product formulation company. Gamma has created, registered and branded innovative product lines that include Nutritional Supplements, Personal Care Products and Over-The-Counter (OTC) pharmaceuticals. At present, Gamma manufactures in North America, and distributes in the United States and China. Gamma's products utilize its patent pending "Gel Delivery Technology(R)"; offering consumers one of the most innovative gel product lines in the market today. Gamma uses its patent pending gel delivery technology to formulate one of the industry's only full suites of gel based products. Gamma benefits from a clear consumer preference for gel product forms; offering consumers a more pleasant experience with product forms that absorb more rapidly, are more convenient and taste great. Market categories Gamma targets are growing as rapidly as 60% per year. Gamma targets consumers in the fast growing Greater China and U.S. wellness and healthcare markets. Primary channels are retail pharmacies, supermarkets, club stores and other big box outlets. Secondary channels include internet and direct selling. Gamma uses third party distributors and sells directly to retail outlets.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.


'/>"/>
SOURCE Gamma Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Study Determines Breast-Specific Gamma Imaging Has Higher Specificity Than MRI in Patients With Equivocal Mammograms
2. Breast-Specific Gamma Imaging (BSGI) Changes Patient Care Management
3. Breast Cancer Imaging Study Indicates Breast-Specific Gamma Imaging (BSGI) Is a Strong Adjunct Imaging Modality to Mammography and Ultrasound
4. Gamma Secretase Modulators Show Promise in Alzheimers Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
5. Gamma Labs to Boost Testosterone At World Series of Poker In Las Vegas
6. Breast-Specific Gamma Imaging (BSGI) Found to Be Highly Sensitive for Early Stage Breast Cancer
7. San Antonio Community Hospital Commissions Leksell Gamma Knife(R) Perfexion(TM) To Serve Over 3 Million Californians
8. Dilon Technologies Signs Amerinet for Breast-Specific Gamma Imaging
9. STERIS Isomedix Services Offers Gamma Engineering Run Program
10. Sugammadex Study First to Show Rapid Reversal of Profound Rocuronium-Induced Muscle Relaxation is Possible
11. Dual-head gamma camera increases ability to detect breast tumors not seen on mammography
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Woodland Hills, CA (PRWEB) , ... December 09, ... ... center for young adults, celebrated its 10th anniversary with the grand opening of ... Hills, California. The successful event spanned two days, December 2-3, and was attended ...
(Date:12/9/2016)... NJ (PRWEB) , ... December 09, 2016 , ... ... Founders Ball at The Pierre Hotel in New York, NY, on December 3rd, ... benefactors, dignitaries and physicians attended the annual event, which raised over $1 million ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Pennsylvania Athletic ... (PCN) during the summer of 2016. The program was made possible by a ... States Department of Health and Human Services Administration. The broadcast, Use Your ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Research Institute (WCRI) officially opened registration today for its 33rd Annual Issues ... Boston, MA . , The theme of the conference is “Persistent Challenges and ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Chester County, a Property owned by an affiliate of Seavest, has won a ... Penn Medicine Southern Chester County ambulatory care center (ACC) was named “Best New ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 Australia Glaucoma ... GlobalData,s new report, "Australia Glaucoma Surgery Devices ... on the Australia Glaucoma Surgery Devices market. The ... volume (in units) and average prices (USD) within ... report also provides company shares and distribution shares ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... poised to grow in 2017-2023. Various reasons for growth ... obese population, higher incidences of chronic diseases, high recovery ... mobility aid services. Medical lifting sling refers to ... with limited mobility. These slings connect to the lift ...
(Date:12/8/2016)... INDIANAPOLIS , Dec. 8, 2016  Eli Lilly ... detailed results of its phase 3 EXPEDITION3 trial at ... (CTAD) meeting. As previously disclosed, solanezumab did not meet ... study of solanezumab initiated in people with mild dementia ... pursue regulatory submissions for solanezumab for the treatment of ...
Breaking Medicine Technology: